# OnCo record nct05271318 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05271318/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05271318", "NCT05271318" ;
  schema:name "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) "@en ;
  schema:alternateName "PROTA"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab, Pegylated liposomal doxorubicin in ovarian cancer, run by TILT Biotherapeutics Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05271318/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05271318> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2022-05-17" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/tilt-123/> ;
  onco:companies <https://onco.cc/companies/tilt-biotherapeutics/> .